市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (SG) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | IX Biopharma | - | - |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.43 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| IX BIOPHARMA | - | - | - | 40.12 |
| TJ DARENTANG USD | - | 27.05% | - | 2.21 |
|
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 50.56% |
| 机构持股比例 | 0.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lee (Yip Hang Eddy) | 04 Sep 2024 | 217,000,852 (24.57%) |
| HRT Corporation Pte. Ltd. | 04 Sep 2024 | 66,748,029 (7.56%) |
| Tang (Choy Leng Jane) | 04 Sep 2024 | 22,793,565 (2.58%) |
| Narulla (Jaspal Singh) | 04 Sep 2024 | 20,727,047 (2.35%) |
| Tan (See Tee) | 04 Sep 2024 | 17,470,800 (1.98%) |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 10 Sep 2026 | TheEdge | Anson Properties ceased to be substantial shareholder of iX Biopharma |
| 06 Sep 2026 | TheEdge | iX Biopharma announces major US regulatory development for Wafermine; US govt opens emergency use pathway |
| 21 Aug 2026 | TheEdge | iX Biopharma reports lower losses of $8 mil for FY2026; near-term priority on EUA application |
| 27 Jul 2026 | TheEdge | OCBC emerges as substantial shareholder of iX Biopharma |
| 15 Jul 2026 | TheEdge | Ahead of the July 17 warrant expiry deadline, iX Biopharma allots 11.7 mil new shares following latest warrant exercise |
| 14 Jul 2026 | TheEdge | iX Biopharma allots close to 2.92 mil new shares following warrant exercise |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合